The Importance of Research – Dr. César Serrano
In this installment of Fueling GIST Research, Dr. César Serrano shares on the importance of GIST research & collaboration among institutions to build a vision of new treatments & a cure.
In this installment of Fueling GIST Research, Dr. César Serrano shares on the importance of GIST research & collaboration among institutions to build a vision of new treatments & a cure.
In this installment of Fueling GIST Research, our Data Management & Research team shares about their management & curation of the LRG GIST Patient Registry which informs patient direction, clinical trials, and research studies.
Our Spring to GIST Awareness Day Campaign Continues! Our spring fundraising campaign is all about Fueling GIST Research and we will be sharing examples of all the ways The Life Raft Group is involved [...]
Our Spring to GIST Awareness Day Campaign Continues! Our spring fundraising campaign is all about Fueling GIST Research and we will be sharing examples of all the ways The Life Raft Group is involved [...]
The LRG published "Barriers to mutational testing in patients with gastrointestinal stromal tumors (GIST) – a survey of Life Raft Group members" in BMC Gastroenterology, November 2022.
In this issue of LRG Science, the relationship between overall survival (OS) and access to treatments after imatinib failure is explored. In 2019, the LRG published this research in Clinical Sarcoma Research and this issue includes commentary from experts. LRG Science endeavors to be a respected source of timely, science-based information built on real world data designed for those whose focus is to increase patient survival from GIST and other cancers.
The latest issue of LRG Science is titled, "First-Line Imatinib More Effective Than Widely Believed - LRG Science - Treatment for Resistant GIST - Improved, but Still Very Far to Go." In this issue, the LRG Real World Evidence team analyzes data from our Patient Registry in order to evaluate the efficacy of imatinib as a first-line treatment in GIST. Subscribe to LRG Science by emailing mgarland@liferaftgroup.org with the subject line SUBSCRIBE LRG SCIENCE.
The latest issue of LRG Science is titled, "Patient-reported Treatment Responses in Known/Likely SDH-deficient GISTS: An Analysis of The Life Raft Group Observational Registry." This study highlights the very unique research role that defines The Life Raft Group. Subscribe to LRG Science by emailing mgarland@liferaftgroup.org with the subject line SUBSCRIBE LRG SCIENCE.
Left to right: Laura Occhiuzzi, Pete Knox, Alyssa O’Driscoll, Sarcoma Alliance, Annie Achee, National LeioMyoSarcoma Foundation, Denise Reinke, SARC, and Mitch Achee, National LeioMyoSarcoma Foundation. GIST Research from CTOS 2018 A web-based [...]
Patient-provided, patient-focused data from the Patient Registry has been a core component of the LRG’s research model. Out of the foundation of real world data, we conducted a Side Effects Survey in the early [...]